2. Metabolic Enzyme/Protease
  3. DAGL
  4. A1480LS

A1480LS is a peripherally restricted, orally active covalent and irreversible inhibitor of DAGLα and DAGLβ, with IC50 values of 6 nM and 4 nM against human targets, respectively, and IC50 values ≤15 nM across mouse, rat, dog, monkey and human systems. A1480LS reduces the levels of 2-arachidonoylglycerol, arachidonic acid, and cyclooxygenase- and lipoxygenase-derived eicosanoids. A1480LS inhibits injury-induced production of 2-arachidonoylglycerol and arachidonic acid in the peripheral sciatic nerve, and suppresses the responses of high-threshold and wide-dynamic-range-like dorsal horn neurons to mechanical stimulation. A1480LS alleviates pain behaviors in rat models of inflammatory pain, neuropathic pain and chemotherapy-induced peripheral neuropathy.

For research use only. We do not sell to patients.

A1480LS

A1480LS Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

A1480LS Related Antibodies

Top Publications Citing Use of Products

View All DAGL Isoform Specific Products:

View All Isoforms
DAGLα DAGLβ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

A1480LS is a peripherally restricted, orally active covalent and irreversible inhibitor of DAGLα and DAGLβ, with IC50 values of 6 nM and 4 nM against human targets, respectively, and IC50 values ≤15 nM across mouse, rat, dog, monkey and human systems. A1480LS reduces the levels of 2-arachidonoylglycerol, arachidonic acid, and cyclooxygenase- and lipoxygenase-derived eicosanoids. A1480LS inhibits injury-induced production of 2-arachidonoylglycerol and arachidonic acid in the peripheral sciatic nerve, and suppresses the responses of high-threshold and wide-dynamic-range-like dorsal horn neurons to mechanical stimulation. A1480LS alleviates pain behaviors in rat models of inflammatory pain, neuropathic pain and chemotherapy-induced peripheral neuropathy[1].

IC50 & Target

DAGLα

 

DAGLβ

 

In Vivo

A1480LS (1-20 mg/kg; p.o.; twice) produces dose-dependent relief of mechanical allodynia in a rat CFA inflammatory pain model by inhibiting peripheral DAGL without altering brain 2-AG levels, with an ED50 of 7.7 mg/kg[1].
A1480LS (15, 20 mg/kg; p.o.) rapidly alleviates and continuously inhibits paclitaxel-induced mechanical hyperalgesia in rats during 5 consecutive days of administration. It also reverses and maintains CCI-induced mechanical allodynia in rats to the sham operation level, while restoring the injury-induced elevated levels of 2-AG and AA in the sciatic nerve to normal, without affecting the levels of these lipids in the brain[1].
A1480LS (1 mg/kg; i.v.) selectively inhibits the activity of HT and WDR-like dorsal horn neurons in anesthetized CCI rats without altering the activity of LTMRs, indicating that it suppresses spinal nociceptive sensory input[1].
A1480LS (8-30 mg/kg; p.o.) does not modulate PTZ-induced seizure susceptibility or brain 2-AG levels in rats, is well tolerated in rats, with only mild, transient reduction in abdominal muscle tone observed in some animals; these findings indicate that it poses no central nervous system epileptogenic risk[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley (male, 176-206 g, intraplantar CFA injection)[1]
Dosage: 1 mg/kg; 2.5 mg/kg; 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: p.o.; 2 doses (2 h before CFA, 24 h after CFA)
Result: Increased mechanical withdrawal thresholds dose-dependently 4 h after the second dose, with an ED50 of 7.7 mg/kg.
Achieved average blood concentrations of 1.1 μM (free plasma concentrations=1.5 nM) at 20 mg/kg, with an EC50 of 0.22 μM to suppress allodynia.
Inhibited kidney DAGLβ activity and reduced kidney 2-AG concentrations dose-dependently.
Caused partial brain DAGLα/β inhibition at 10 and 20 mg/kg without brain 2-AG depletion.
Animal Model: Sprague Dawley (male, intraperitoneal paclitaxel injection 1 mg/kg daily for 5 consecutive days)[1]
Dosage: 15 mg/kg (single dose; established allodynia); 15 mg/kg (repeated dosing; maintained anti-allodynic effects)
Administration: p.o.; single dose on day 7; once daily for 5 days (days 15-18)
Result: Attenuated established mechanical allodynia 4 h post-dose on day 7 with a single 15 mg/kg oral dose.
Maintained significant anti-allodynic effects over 5 days with repeated once-daily dosing of 15 mg/kg from days 15-18, comparable to duloxetine.
Animal Model: Sprague Dawley (male, 200-220 g at surgery; 233-289 g at dosing, chronic constriction injury of left common sciatic nerve)[1]
Dosage: 20 mg/kg (repeated dosing; allodynia reversal); 20 mg/kg (single dose; lipid analysis)
Administration: p.o.; once daily for 5 days (days 14-18); single dose 14 days post-CCI
Result: Reversed allodynia and restored von Frey thresholds to sham levels with repeated 20 mg/kg dosing, with efficacy comparable to naproxen and pregabalin.
Reduced 2-AG and normalized AA concentrations in injured sciatic nerves with a single 20 mg/kg dose, after CCI caused a 7-fold increase in 2-AG and 2-fold increase in AA.
Animal Model: Sprague Dawley (male, 250-315 g, chronic constriction injury of left sciatic nerve, right jugular vein catheter implantation)[1]
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
Administration: i.v.; single bolus after baseline vehicle recording
Result: Produced dose-dependent modulation of high-threshold (HT) and wide dynamic range-like (WDR-like) single-unit responses, with robust suppression at 1 mg/kg.
Did not modulate low-threshold mechanoreceptor (LTMR) single-unit activity at 1 mg/kg.
Animal Model: Sprague Dawley (male, 208-263 g, subcutaneous pentylenetetrazole injection 80 mg/kg)[1]
Dosage: 8 mg/kg; 16 mg/kg; 30 mg/kg
Administration: p.o.; single dose 4 h pre-PTZ
Result: Did not alter convulsion latency or occurrence at any tested dose.
Did not change brain 2-AG levels following administration.
Molecular Weight

542.55

Formula

C30H25F3N6O
SMILES

O=C(N1CCN(C[C@@H]1CC2=CC=CC=C2)C3=NC(C(F)(F)F)=CN=C3)N4C=C5C=C(C=CC5=N4)C6=CC=CC=C6
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

A1480LS Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

A1480LSDAGLDiacylglycerol lipaseDAG lipaseDGLsciatic nervesDAGLαDAGLβarachidonic acidneuropathic paincyclooxygenaselipoxygenase2-arachidonoylglyceroldorsal horn neuroninflammatory painInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
A1480LS
Cat. No.:
HY-181482
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.